Serum lipids and apolipoproteins A1 and B in Adventist students in Argentina;Lípidos y apolipoproteínas A-l y B séricos en escolares adventistas de la República Argentina

Acta Bioquimica Clinica Latinoamericana

Volumn 37, Issue 1, 2003, Pages 5-12

  Aguilar, Daniel A ^a,b,d   Yáñez, Carlos D ^a,b   Bina Estrada, Marta R ^a   Dilenque, Silvia ^a   Peterson, Graciela ^c   Tavella, Marcelo ^c  

^a Universidad Adventista del Plata   (Argentina)

^b Sanatorio Adventista del Plata   (Argentina)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^d Sanatorio Adventista del Plata   (Argentina)

Author keywords

Adventist; Apolipoprotein AI; Apolipoprotein B; Children; Risk factors

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LIPID;

AGE DISTRIBUTION; ARGENTINA; ARTICLE; ATHEROGENESIS; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; RELIGION; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

EID: 0037622712     PISSN: 03252957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of Apo A- and Apo B- containing lipoprotein families. Prog Lipid Res 1991; 30: 105-38.
2. Tavella M, Alaupovic P, Knight-Gibson C, Tournier H, Schinella G, Mercuri O. Separation of Apo A- and Apo B- containing lipoproteins of human plasma by affinity chromatography on concanavalin A. Prog Lipid Res 1991; 130: 181-7.
3. Alaupovic P, McConathy WJ, Fesmire J, Tavella M, Bard JM. Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias. Clin Chem 1988; 34: 13-27.
4. Alaupovic P, Blanckenhorn DH, Knight-Gibson C, Tavella M, Bard JM, Shafer D, et al. Apo B- Containing lipoprotein particles as risk factors for coronary artery disease. Adv Exp Med Biol 1991; 285: 299-309.
5. Alaupovic P, Bard JM, Tavella M, Shafer D. Identification of apoB-containing lipoprotein families in NIDDM. Diabetes 1992; 41: 18-25.
6. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. Increased concentrations of Apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure. Miner Electrolyte Metab 1992; 18: 199-202.
7. Blankenhorn DH, Seizer RH, Crawford DW, Barth JD, Liu CR, Liu CH, et al. Beneficial effects of colestipolniacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88: 20-8.
8. Attman PO, Alaupovic P, Samuelsson O. Lipoprotein abnormalities as a risk factor for progessive nondiabetic renal disease. KidneyInt Suppl 1999; 71: 14-7.
9. Corder CN, Tavella M, McConathy W, Alaupovic P, Johnson M. Effect of probucol therapy on plasma fatty acid composition during postprandial lipemia in hypertriglyceridemia. Am J Ther 1997; 4: 247-54.
10. Fruchart JC, Ailhaud G. Apolipoprotein A-Containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem 1992; 38(6): 793-7.
11. McGill HC. The pathogenesis of atherosclerosis. Clin Chem 1988; 34: 33-9.
12. Strong JP and PDAY Research Group. Natural history and risk factors for early human atherogenesis. Clin Chem 1995; 41: 134-8.
13. Berenson GS, Srinivisan SR, Nicklas TA, Webber LS. Cardiovascular risk factor in children and early prevention of heart disease. Clin Chem 1988; 34: 115-22.
14. Srinivisan SR, Freedman DS, Sharma C, Webber LS, Berenson GS. Serum apolipoproteins A-I and B in 2854 children from a biracial community: Bogalusa Heart Study. Pediatrics 1986; 78: 189-200.
15. Solakivi-Jaakkola T, Nikari T, Viikari HK, Rasanen L, Uhari M, Dahl M, et al. Atherosclerosis precursors in Finish children and adolescents. VI. Serum apolipoproteins A-I and B. Acta Paediatr Scand Suppl 1985; 318: 119-25.
16. Morales San José MT, Sánchez Bayle M, Peláez Gómez de Salazar MJ, Puente Barral MJ, Ruiz-Jarabo Quemada C, Asensio Anton J. The value of lipid profile and of CT/C-HDL, C-LDL/C-HDL, Apo B/A indexes and atherogenic index in 6-year-old children from Rivas-Vaciamadrid. An Esp Pediatr 1988; 49: 140-4.
17. Leino A, Impivaara O, Kaitsaari M, Järvisalo J. Serum concentrations of apolipoprotein A-I, apolipoprotein B and lipoprotein (a) in a population sample. Clin Chem 1995; 41: 1633-6.
18. Graziani ME, Zanolla L, Righetti G, Marchetti C, Mocarelli P, Marcovina SM. Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group. Clin Chem 1998; 44: 134-40.
19. Lynch JF, Marshall MD, Wang XL, Wilcken DE. Apolipoprotein screening in Australian children: feasibility and the effect of age, sex and ethnicity. Med J Aust 1998; 168: 61-4.
20. Dennison BA, Kikuchi DA, Srinivasan SR, Webber LS, Berenson GS. Measurement of apolipoprotein B as markers a screening test for identifying children with elevated levels of low density lipoprotein cholesterol. J Pediatr 1990; 117: 358-63.
21. Organización Panamericana de la Salud. Las condiciones de salud en las Américas. Publicación Científica de la OPS N° 524; 1990.
22. Ministerio de Salud y Acción Social de Argentina. Boletín Informativo N° 38, Serie 5; 1995.
23. Harman SK, Parnell WR. The nutritional health of New Zealand vegetarian and non-vegetarian Seventh Day Adventists: selected vitamin, mineral and lipid levels. NZ Med J 1998; 111: 91-4.
24. Fraser GE, Sumburer D, Pribis P, Neil RL, Frankson MA. Association among Health habits, risk factors, and all-cause mortality in a black California population. Epidemiology 1997; 8: 168-74.
25. Fonnebo V. The healthy Seventh-Day Adventist lifestyle: what is the Norwegian experience? Am J Clin Nutr 1994; 59: 1124-9.
26. Fraser GE. Diet and coronary heart disease: beyond dietary fats and low-density-lipoprotein cholesterol. Am J Clin Nutr 1994; 59: 1117-23.
27. Fraser GE, Strahan TM, Sabate J, Beeson, WL, Kissinger D. Effects of traditional coronary risk factors on rates of incident coronary events in a low-risk population. The Adventist Health Study. Circulation 1992; 86: 406-13.
28. Fraser GE, Sabate J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study, Arch. Intern Med 1992; 152: 1416-24.
29. Resnicow K, Barone J, Engle A, Miller S, Haley NJ, Fleming D, et al. Diet and serum lipids in vegan vegetarians: a model for risk reduction. J Am Diet Assoc 1991; 91: 447-53.
30. Sellés J, Coniglio I, Álvarez C, Benozzi S. Lipoproteína (a), apolipoproteína B y colesterol LDL en preadolescentes con y sin historia familiar de aterosclerosis: efecto del colesterol de Lp(a) sobre los valores de C-LDL. Acta Bioquím Clín Latinoam 1999; 33: 339-49.
31. Sellés J, Coniglio I, Álvarez C, Betcher G, Perticarini L. Detección temprana de niños y jóvenes con riesgo de enfermedad coronaria en la adultez. Arch Argent Pediatr 1997; 95: 76-83.
32. Schcolnik C, Pouso J, Mastropierro M. Parámetros lipídicos en diferentes edades de una población de la República Oriental del Uruguay. Clin Invest Arteriosclerosis 2000; 12: 77-82.
33. Dahinten E, Coniglio RI. Factores de riesgo para la aterosclerosis en una población pediátrica de Comodoro Rivadavia. Acta Bioquím Clín Latinoam 1997; 31: 29-138.
34. Casanueva V, Cid X, Calvo C, Chiang MT, Ulloa N, Milos C, et al. Lipoprotein in children and adolescents: relation with familiar history of coronary disease. Rev Méd Chile 1996; 124: 799-804.
35. Casanueva V, Cid X, Milos C, Chiang MT, Ruiz C, Marivil P, et al. Serum concentration of A-I and B apolipoprotein in children and adolescents. Rev Chil Pediatr 1995; 66: 200-3.
36. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and A-I distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NANHES III). Clin Chem 1997; 43: 2364-78.